Non-Invasive Prenatal Testing Market Share, Strategies

Non-Invasive Prenatal Testing Market

Non-Invasive Prenatal Testing Market: Introduction

Transparency Market Research has released a new report titled “Global Non-Invasive Prenatal Testing Market”. According to the report, the global non-invasive prenatal testing market was valued at approximately US$1.3 billion in 2018. The global non-invasive prenatal testing market is expected to grow at a CAGR of 16.4% during the period. forecast from 2019 to 2027. .

Get a sample copy of the report @


Rising prevalence of chronic diseases, such as cancer and diabetes, has increased the patient pool, followed by an increase in demand for biologic drugs for the treatment of various chronic diseases, which has driven the growth of the non-invasive prenatal testing market

The market is expected to witness high growth from 2019 to 2027. Rising demand for early and non-invasive procedures is also considered a major driver driving the global NIPT market. For pregnant women at high risk of fetal chromosomal abnormalities (women aged 35 and over, personal or family history of aneuploidy and positive result with the conventional screening method), it is very important to make a decision at an early stage. early, as delay can lead to pain and discomfort as well as developmental problems with the fetus.
The growing demand for early detection is expected to trigger the demand for NIPT globally, as most of the NIPT available in the market can be recommended as early as 9-10 weeks of gestation. Traditional invasive prenatal tests, such as amniocentesis and chronic villus sampling (CVS), are associated with the risk of miscarriage. Due to the fact that NIPTs completely eliminate the risk of miscarriage, they are increasingly preferred by women over invasive prenatal tests.

Globally, the average age of first-time mothers is increasing, especially in developed countries such as the United States, United Kingdom, France, Germany, Italy and Japan. Financial stability, rising literacy rates and social factors are the main factors responsible for advanced maternal age. The risk of fetal chromosomal aneuploidies is directly related to increasing maternal age.
Rising maternal age and advantages of NIPT over traditional invasive tests are some of the factors responsible for the growth of the market

Survey before buying @

Materni21 test type segment will dominate the global market

By type of test, the MaterniT21 segment accounted for a significant share of the global non-invasive prenatal testing market in 2018.

The segment’s dominance in the global market is attributed to the strong reputation of the MaterniT21 brand and the acquisition of Sequenom by Labcorp.

In the United States, Sequenom (currently part of Labcorp) introduced MateriT21 in 2011, which was the first NIPT solution in the United States. MaterniT21 is able to identify trisomies and extensive testing may also explain sex chromosome disabilities and some microdeletions. Less percentage error is a significant advantage of MaterniT21. Besides MaterniT21, the panorama segment held a notable market share, in terms of volume, in 2018.

Get report methodology @

Trisomy tests to witness high adoption during the forecast period

Based on applications, Down syndrome segment held a major share in 2018 in the non-invasive prenatal testing market. The segment is expected to be very lucrative during the forecast period.

According to the United Nations, the estimated incidence rate of Down syndrome ranges from 1 in 1,000 live births per year to 1 in 1,100 live births per year. About 95% of Down syndrome cases are nondisjunction cases, while translocation and mosaicism cases make up the remaining 5%.

The predominance of the trisomy segment is attributable to the increasing prevalence of Down syndrome worldwide and the high efficiency of NIPT for screening for Down syndrome.

Global Non-Invasive Prenatal Testing Market: Important Regions

North America held the largest share of the global non-invasive prenatal testing market in 2018. North America accounted for a major share of the global non-invasive prenatal testing market in 2018. The market in the region is expected to grow at a rapid pace over the forecast period.

The market in the region is driven by the presence of key players, a large number of research activities and a highly structured healthcare industry
Increasing investments by key players in North America and increasing maternal age are expected to propel the North America non-invasive prenatal testing market

The United States is expected to dominate the non-invasive prenatal testing market in the region over the forecast period, owing to the early adoption of the technologies. The country is expected to be the most attractive market for non-invasive prenatal testing, with a high attractiveness index.

Well-equipped hospitals, technological advancements, increase in research and development in non-invasive prenatal tests for new applications, and increase in demand for new products and treatments are expected to improve the non-invasive prenatal tests market in the United States. United.

Read the report preview @

Global Non-Invasive Prenatal Testing Market: Key Players

The players are strengthening their product portfolio and collaborating with other companies to secure and strengthen their positions in the non-invasive prenatal screening market. For example, in July 2018, Berry Genetics partnered with 10X Genomics to upgrade non-invasive prenatal DNA testing. This collaboration was the first step in the entry of 10X Genomics into the Chinese market.

In July 2016, Laboratory Corporation announced the acquisition of Sequenom for US$371 million including debt. With this acquisition, Laboratory Corporation would strengthen its presence outside the United States, Europe and Asia-Pacific, and enable it to provide superior NIPT services.

Key players operating in the global non-invasive prenatal testing market include Berry Genetics, BGI, Laboratory Corporation of America Holdings, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, NATERA, INC., PerkinElmer Inc. , Eurofins LifeCodexx AG and IGENOMIX.

Get a personalized research report @

The global non-invasive prenatal testing market has been segmented as follows:

Global Non-Invasive Prenatal Testing Market, By Test Type


Global Non-Invasive Prenatal Testing Market, By Application

Symptoms of microdeletions
Other (including sex chromosome disorders)

Global Non-Invasive Prenatal Testing Market, By Technology


Global Non-Invasive Prenatal Testing Market, By End User

Diagnostic laboratories

About Us

Transparency Market Research, a global market research firm registered in Wilmington, Delaware, USA, provides personalized research and advisory services. The company examines the factors that shape demand dynamics in various markets. Market insights and insights assess opportunities in various segments. Opportunities in segments based on source, application, demographics, sales channel, and end-use are analyzed which will determine the growth of the markets over the next decade.

Our proprietary blend of quantitative forecasting and trend analysis delivers forward-looking insights to thousands of decision makers, made possible by experienced teams of analysts, researchers and consultants. Proprietary data sources and the various tools and techniques we use always reflect the latest trends and information. With a broad research and analytical capability, Transparency Market Research uses rigorous primary and secondary research techniques in all of its trade reports.

For more information on research on leading industries, visit our YouTube channel and click subscribe for future update –


Rohit Bhisey
Transparency Market Research Inc.
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
United States – Canada Toll Free: 866-552-3453
Email: [email protected]

This press release was published on openPR.

Comments are closed.